Novaremed Enters Into an Exclusive Option and License Agreem

Novaremed Enters Into an Exclusive Option and License Agreement With NeuroFront for the Non-opioid Neuropathic Pain Treatment, NRD.E1, for Greater China and Singapore

Novaremed Enters Into an Exclusive Option and License Agreement With NeuroFront for the Non-opioid Neuropathic Pain Treatment, NRD.E1, for Greater China and Singapore
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

China , Taiwan , Hong Kong , Switzerland , Singapore , Macau , Mark Altmeyer , June Yan , Isaac Kobrin , Clinical Pharmacology In Drug Development , Metys Pharmaceuticals Ag Switzerland , Company Investment House , Novaremed Ltd Israel , National Institutes Of Health , Neurofront Therapeutics Hong Kong , Nan Fung Life Sciences , Wall Street , Greater China , Neurofront Therapeutics , Mainland China , Executive Chairman , Track Designation , Company Investment , Fast Track Designation , National Institutes , Help End Long Term Addiction , Venture Partners China , Novaremed Ltd , Metys Pharmaceuticals , Drug Development , Executive Member ,